2024-515365-34-00招募中4 期
The DENOCHARCOT trial. Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial.
Region Hovedstaden, Region Hovedstaden8 个研究点 分布在 1 个国家目标入组 114 人开始时间: 2024年7月4日最近更新:
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 114
- 试验地点
- 8
- 主要终点
- Time from first injection of IP until the time point where the acute Charcot foot is clinically healed/in remission, ie. the temperature difference at the site maximum temperature on the affected Charcot foot is < 2 degrees Celsius compared to the similar site on the contra-lateral foot, measured using an infrared thermometer, and edema and redness of the skin has subsided – at two subsequent visits 4 weeks apart.
研究概览
简要总结
The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Age 18-80 years AND Type 1 or type 2 diabetes (diagnosed diabetes for more than 3 months) AND Diagnosed with acute Charcot foot defined as a unilateral red, swollen and warm foot, with a difference of skin temperature of more than 2 °C compared with the unaffected foot and with sign of Charcot on either x-rays of the foot, MRI, bone scintigram or PET/CT and Peripheral neuropathy: Previously diagnosed and/or biothesiometri: > 25 V or lack of sensation of 10 grams monofilament on
- •toe at the acute Charcot foot.
排除标准
- •Duration of the acute Charcot foot for more than 3 months (at the screening visit). • Existing foot ulcer on the affected foot, unless the ulcer is very superficial, in healing and with no signs of infection and no increased surrounding skin temperature compared to the contralateral foot. • Previous acute or chronic Charcot of the affected foot • Planned surgery on the acute Charcot foot • Infection (cellulitis or osteomyelitis) of the affected foot (clinically and/or radiologically proven) • Previous midfoot or proximal to mid foot amputation of the affected foot • Hypocalcemia (Serum Calcium <2.1 mmol/L or Calcium ion < 1.12 mmol/L) • Vitamin D deficiency (Serum 25-hydroxyvitamin D < 50 nmol/L) • Renal failure (serum creatinine >200 mmol/L or eGFR < 30 ml/min). • Treatment with Denosumab within the last 12 months. • Have a known hypersensitivity to Denosumab • History of osteonecrosis of the jaw. • Poor oral hygiene, which is defined as within 3 months of a tooth extraction, dental implants or mandibular surgery • Planned mandibular surgery or dental implants within the next 12 months. • Prior non-traumatic vertebral fracture • Treatment with medication known to affect bones within the last 12 months (such as bisphosphonates, Forsteo®, calcitonin, Protelos®, selective estrogen receptor modulators, glucocorticoids and sex hormones) • Active or chronic liver disease *Chronic liver disease is defined as clinical history of decompensated chronic liver disease (ascites, encephalopathy or variceal bleeding) *Acute Liver disease is defined as an INR of > 1.5 (in the absence of the use of Warfarin) and AST and ALT > 2 x ULN • History of inflammatory arthropathies (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, autoimmune arthropathy) • Pre-existing medical condition judged to preclude safe participation in the study • Current treatment with cytotoxic drugs or with systemically administered glucocorticoids • Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocol • Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods. The following contraceptive products are considered to be safe: Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections). • Likely inability to comply with the visits because of planned activity • Use of any investigational product with the last month. • Use of any drug or any other reason which in the Investigator’s opinion could interfere with the outcome of the treatment of the acute Charcot foot. • Cancer, or any clinically significant disease or disorder, except for conditions associated to the diabetes, which in the Investigator’s opinion could interfere with the results of the trial
结局指标
主要结局
Time from first injection of IP until the time point where the acute Charcot foot is clinically healed/in remission, ie. the temperature difference at the site maximum temperature on the affected Charcot foot is < 2 degrees Celsius compared to the similar site on the contra-lateral foot, measured using an infrared thermometer, and edema and redness of the skin has subsided – at two subsequent visits 4 weeks apart.
Time from first injection of IP until the time point where the acute Charcot foot is clinically healed/in remission, ie. the temperature difference at the site maximum temperature on the affected Charcot foot is < 2 degrees Celsius compared to the similar site on the contra-lateral foot, measured using an infrared thermometer, and edema and redness of the skin has subsided – at two subsequent visits 4 weeks apart.
次要结局
- Fraction of clinical healed participants at each study visit. Fraction of healing on X-rays and MRI (or PET/CT or Scintigram) at the time of clinical healing and at the End of trial. Number of relapses (defined as need for/prescription of off- loading with cast of the Charcot foot again) ...
研究者
Ole Lander Svendsen
Scientific
Bispebjerg Hospital, Department of Endocrinology
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
1 期
The DENOCHARCOT trial. Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial.diabetic acute Charcot foot (Charcot neuroarthropathy)CTIS2024-515365-34-00Bispebjerg Hospital, Department of Endocrinology114
已完成
3 期
Evaluation of the efficacy of defroxamine- deferiprone on cardiac function in patients with thalassemia majorThalassemia major.Beta thalassemia majorIRCT2014070512765N4Golestan University of Medical Sciences12
已完成
4 期
ow dose DEC as an alternative to current dose used in Lymphatic Filariasis programCTRI/2014/02/004375Regional Medical Research Centre ICMR900
已完成
不适用
A clinical trial evaluating of effect of Descurainia sophia (L.) on clinical symptoms of adult patients with functional constipatioRelationship of Descurainia sophia L. with functional constipation in adults.IRCT2016030515408N2School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center, Shahid Be35
招募中
2 期
The reduction in the number of attacks in multiple sclerosis patientsMultiple sclerosisMultiple sclerosis patients.IRCT20190121042439N1Mashhad University of Medical Sciences40